|
|
Line 3: |
Line 3: |
| <StructureSection load='5wgk' size='340' side='right'caption='[[5wgk]], [[Resolution|resolution]] 1.82Å' scene=''> | | <StructureSection load='5wgk' size='340' side='right'caption='[[5wgk]], [[Resolution|resolution]] 1.82Å' scene=''> |
| == Structural highlights == | | == Structural highlights == |
- | <table><tr><td colspan='2'>[[5wgk]] is a 1 chain structure with sequence from [http://en.wikipedia.org/wiki/Brachidanio_rerio Brachidanio rerio]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5WGK OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5WGK FirstGlance]. <br> | + | <table><tr><td colspan='2'>[[5wgk]] is a 1 chain structure with sequence from [https://en.wikipedia.org/wiki/Danio_rerio Danio rerio]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5WGK OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=5WGK FirstGlance]. <br> |
- | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=AGJ:N-hydroxy-4-{[(2-hydroxyethyl)(phenylacetyl)amino]methyl}benzamide'>AGJ</scene>, <scene name='pdbligand=EDO:1,2-ETHANEDIOL'>EDO</scene>, <scene name='pdbligand=IOD:IODIDE+ION'>IOD</scene>, <scene name='pdbligand=K:POTASSIUM+ION'>K</scene>, <scene name='pdbligand=PEG:DI(HYDROXYETHYL)ETHER'>PEG</scene>, <scene name='pdbligand=ZN:ZINC+ION'>ZN</scene></td></tr> | + | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 1.822Å</td></tr> |
- | <tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">hdac6 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=7955 Brachidanio rerio])</td></tr>
| + | <tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=AGJ:N-hydroxy-4-{[(2-hydroxyethyl)(phenylacetyl)amino]methyl}benzamide'>AGJ</scene>, <scene name='pdbligand=EDO:1,2-ETHANEDIOL'>EDO</scene>, <scene name='pdbligand=IOD:IODIDE+ION'>IOD</scene>, <scene name='pdbligand=K:POTASSIUM+ION'>K</scene>, <scene name='pdbligand=PEG:DI(HYDROXYETHYL)ETHER'>PEG</scene>, <scene name='pdbligand=ZN:ZINC+ION'>ZN</scene></td></tr> |
- | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5wgk FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5wgk OCA], [http://pdbe.org/5wgk PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5wgk RCSB], [http://www.ebi.ac.uk/pdbsum/5wgk PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5wgk ProSAT]</span></td></tr> | + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=5wgk FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5wgk OCA], [https://pdbe.org/5wgk PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=5wgk RCSB], [https://www.ebi.ac.uk/pdbsum/5wgk PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=5wgk ProSAT]</span></td></tr> |
| </table> | | </table> |
| + | == Function == |
| + | [https://www.uniprot.org/uniprot/F8W4B7_DANRE F8W4B7_DANRE] |
| <div style="background-color:#fffaf0;"> | | <div style="background-color:#fffaf0;"> |
| == Publication Abstract from PubMed == | | == Publication Abstract from PubMed == |
Line 24: |
Line 26: |
| __TOC__ | | __TOC__ |
| </StructureSection> | | </StructureSection> |
- | [[Category: Brachidanio rerio]] | + | [[Category: Danio rerio]] |
| [[Category: Large Structures]] | | [[Category: Large Structures]] |
- | [[Category: Christianson, D W]] | + | [[Category: Christianson DW]] |
- | [[Category: Porter, N J]] | + | [[Category: Porter NJ]] |
- | [[Category: Histone deacetylase]]
| + | |
- | [[Category: Hydrolase inhibitor]]
| + | |
- | [[Category: Hydrolase-hydrolase inhibitor complex]]
| + | |
| Structural highlights
5wgk is a 1 chain structure with sequence from Danio rerio. Full crystallographic information is available from OCA. For a guided tour on the structure components use FirstGlance.
| Method: | X-ray diffraction, Resolution 1.822Å |
Ligands: | , , , , , |
Resources: | FirstGlance, OCA, PDBe, RCSB, PDBsum, ProSAT |
Function
F8W4B7_DANRE
Publication Abstract from PubMed
Histone deacetylases (HDACs) regulate myriad cellular processes by catalyzing the hydrolysis of acetyl-l-lysine residues in histone and nonhistone proteins. The Zn(2+)-dependent class IIb enzyme HDAC6 regulates microtubule function by deacetylating alpha-tubulin, which suppresses microtubule dynamics and leads to cell cycle arrest and apoptosis. Accordingly, HDAC6 is a target for the development of selective inhibitors that might be useful in new therapeutic approaches for the treatment of cancer, neurodegenerative diseases, and other disorders. Here, we present high-resolution structures of catalytic domain 2 from Danio rerio HDAC6 (henceforth simply "HDAC6") complexed with compounds that selectively inhibit HDAC6 while maintaining nanomolar inhibitory potency: N-hydroxy-4-[(N(2-hydroxyethyl)-2-phenylacetamido)methyl)-benzamide)] (HPB), ACY-1215 (Ricolinostat), and ACY-1083. These structures reveal that an unusual monodentate Zn(2+) coordination mode is exploited by sterically bulky HDAC6-selective phenylhydroxamate inhibitors. We additionally report the ultrahigh-resolution structure of the HDAC6-trichostatin A complex, which reveals two Zn(2+)-binding conformers for the inhibitor: a major conformer (70%) with canonical bidentate hydroxamate-Zn(2+) coordination geometry and a minor conformer (30%) with monodentate hydroxamate-Zn(2+) coordination geometry, reflecting a free energy difference of only 0.5 kcal/mol. The minor conformer is not visible in lower resolution structure determinations. Structural comparisons of HDAC6-inhibitor complexes with class I HDACs suggest active site features that contribute to the isozyme selectivity observed in biochemical assays.
Unusual zinc-binding mode of HDAC6-selective hydroxamate inhibitors.,Porter NJ, Mahendran A, Breslow R, Christianson DW Proc Natl Acad Sci U S A. 2017 Dec 4. pii: 1718823114. doi:, 10.1073/pnas.1718823114. PMID:29203661[1]
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
See Also
References
- ↑ Porter NJ, Mahendran A, Breslow R, Christianson DW. Unusual zinc-binding mode of HDAC6-selective hydroxamate inhibitors. Proc Natl Acad Sci U S A. 2017 Dec 4. pii: 1718823114. doi:, 10.1073/pnas.1718823114. PMID:29203661 doi:http://dx.doi.org/10.1073/pnas.1718823114
|